TABLE 1

Overview of individual data sets included in this studya

StudyReferenceShort descriptionData type
IHMP, 2012 (10)Samples of healthy individuals (n = 154)MG
IIVogtmann et al., 2016 (11)CRC (n = 52) vs controls (n = 52)MG
IIIaLe Chatelier et al., 2013 (4)Obese (n = 169) vs controls (n = 123)MG
IIIbQin et al., 2010 (19)UC (n = 21), CD (n = 4) vs controls (n = 14)MG
IVKarlsson et al., 2013 (12)T2D (n = 53) vs controls (n = 49)MG
VZeller et al., 2014 (13)CRC (n = 91) vs controls (n = 66)MG
VIBäckhed et al., 2015 (8)Mothers (n = 100) and their infants, 1 wk (n = 98), 4 and 12 mo (n = 100 each)MG
VIIKarlsson et al., 2012 (5)CVD (n = 13) vs controls (n = 12)MG
VIIIQin et al., 2012 (3)T2D (n = 182) vs controls (n = 185)MG
IXQin et al., 2014 (14)Cirrhosis (n = 123) vs controls (n = 114)MG
XFranzosa et al., 2014 (15)MG and MT of 8 individualsMG/MT
XIDavid et al., 2013 (16)10 subjects receiving plant-based and animal-product-based dietsMT
XIIForslund et al., 2015 (18)T2D (n = 75), T1D (n = 31) vs controls from IIIMG
XIIIRaymond et al., 2015 (20)Antibiotic treatment (n = 18) vs controls (n = 6)MG
XIVZhang et al., 2015 (21)Dietary intervention in simple (diet-related, n = 21) and genetic (n = 17) obesityMG
XVLi et al., 2016 (22)Fecal transplantation (n = 5) vs placebo (n = 5)MG
  • a For more details, see Table S1. Abbreviations: CRC, colorectal cancer; UC, ulcerative colitis; CD, Crohn’s disease; T1(2)D, type 1 (type 2) diabetes; CVD, cardiovascular disease; MG, metagenomic data; MT, metatranscriptomic data; HMP, Human Microbiome Project.